Xiao-Yuan Dai Perrard1, Zeqin Lian1, George Bobotas2, Mary R Dicklin3, Kevin C Maki3, Huaizhu Wu4. 1. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 2. Matinas BioPharma, Inc, Bedminster, NJ, USA. 3. Midwest Biomedical Research/Center for Metabolic and Cardiovascular Health, Glen Ellyn, IL, USA. 4. Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. Electronic address: hwu@bcm.edu.
Abstract
BACKGROUND:Hypertriglyceridemia increases risk for atherosclerotic cardiovascular disease and may contribute to atherosclerosis by changing circulating monocyte phenotypes. High-dose n-3 polyunsaturated fatty acids reduce blood triglyceride levels. Effects of triglyceride-lowering therapy on monocyte phenotypes are not well known. OBJECTIVE: We examined effects of n-3 polyunsaturated fatty acid treatments (eicosapentaenoic acid [EPA] plus docosapentaenoic acid [MAT9001] vs EPA ethyl esters [EPA-EE]) on monocyte phenotypes in individuals with hypertriglyceridemia. METHODS:Individuals with triglycerides 200 to 400 mg/dL were recruited. Subjects received 2 treatments in randomized order for 14 days each: MAT9001 and EPA-EE, at 4 g/d. At 2 days before the start of, and on the last day of, each treatment, nile red staining for lipids and phenotypes of each monocyte subset were examined by flow cytometry after an overnight fast and postprandially after a high-fat meal. RESULTS: Treatment with MAT9001 or EPA-EE reduced fasting triglyceride levels and decreased proportions of intermediate monocytes. Only MAT9001 decreased postprandial blood triglyceride levels, lowered fasting nile red levels, indicating less lipid in classical and intermediate monocytes, and reduced postprandial CD11c levels on nonclassical monocytes. MAT9001 and EPA-EE each reduced fasting and postprandial CD11c and CD36 levels on classical and intermediate monocytes and postprandial CCR5 levels on intermediate and nonclassical monocytes, with no significant differences between the 2 treatments. CONCLUSIONS: Treatment with MAT9001 in individuals with hypertriglyceridemia reduced fasting nile red staining for lipids in classical and intermediate monocytes. MAT9001 and EPA-EE each improved fasting and postprandial monocyte phenotypes, which could potentially help to protect against atherosclerosis.
RCT Entities:
BACKGROUND:Hypertriglyceridemia increases risk for atherosclerotic cardiovascular disease and may contribute to atherosclerosis by changing circulating monocyte phenotypes. High-dose n-3 polyunsaturated fatty acids reduce blood triglyceride levels. Effects of triglyceride-lowering therapy on monocyte phenotypes are not well known. OBJECTIVE: We examined effects of n-3 polyunsaturated fatty acid treatments (eicosapentaenoic acid [EPA] plus docosapentaenoic acid [MAT9001] vs EPA ethyl esters [EPA-EE]) on monocyte phenotypes in individuals with hypertriglyceridemia. METHODS: Individuals with triglycerides 200 to 400 mg/dL were recruited. Subjects received 2 treatments in randomized order for 14 days each: MAT9001 and EPA-EE, at 4 g/d. At 2 days before the start of, and on the last day of, each treatment, nile red staining for lipids and phenotypes of each monocyte subset were examined by flow cytometry after an overnight fast and postprandially after a high-fat meal. RESULTS: Treatment with MAT9001 or EPA-EE reduced fasting triglyceride levels and decreased proportions of intermediate monocytes. Only MAT9001 decreased postprandial blood triglyceride levels, lowered fasting nile red levels, indicating less lipid in classical and intermediate monocytes, and reduced postprandial CD11c levels on nonclassical monocytes. MAT9001 and EPA-EE each reduced fasting and postprandial CD11c and CD36 levels on classical and intermediate monocytes and postprandial CCR5 levels on intermediate and nonclassical monocytes, with no significant differences between the 2 treatments. CONCLUSIONS: Treatment with MAT9001 in individuals with hypertriglyceridemia reduced fasting nile red staining for lipids in classical and intermediate monocytes. MAT9001 and EPA-EE each improved fasting and postprandial monocyte phenotypes, which could potentially help to protect against atherosclerosis.
Authors: Dominic E Warrino; Louis J DeGennaro; Mary Hanson; Susan Swindells; Samuel J Pirruccello; Wayne L Ryan Journal: J Immunol Methods Date: 2005-10-30 Impact factor: 2.303
Authors: Kyrill S Rogacev; Christof Ulrich; Lutz Blömer; Florian Hornof; Katrin Oster; Maren Ziegelin; Bodo Cremers; Yvonne Grenner; Jürgen Geisel; Axel Schlitt; Hans Köhler; Danilo Fliser; Matthias Girndt; Gunnar H Heine Journal: Eur Heart J Date: 2009-08-17 Impact factor: 29.983
Authors: Amanda L Brown; Xuewei Zhu; Shunxing Rong; Swapnil Shewale; Jeongmin Seo; Elena Boudyguina; Abraham K Gebre; Martha A Alexander-Miller; John S Parks Journal: Arterioscler Thromb Vasc Biol Date: 2012-07-19 Impact factor: 8.311
Authors: Frederic Geissmann; Markus G Manz; Steffen Jung; Michael H Sieweke; Miriam Merad; Klaus Ley Journal: Science Date: 2010-02-05 Impact factor: 47.728
Authors: John J P Kastelein; Kevin C Maki; Andrey Susekov; Marat Ezhov; Borge G Nordestgaard; Ben N Machielse; Douglas Kling; Michael H Davidson Journal: J Clin Lipidol Date: 2013-10-14 Impact factor: 4.766
Authors: Chongxiu Sun; Scott I Simon; Greg A Foster; Christopher E Radecke; HyunTae V Hwang; Xiaodong Zhang; Bruce D Hammock; N Chiamvimonvat; Anne A Knowlton Journal: J Mol Cell Cardiol Date: 2016-04-11 Impact factor: 5.000
Authors: Zeqin Lian; Xiao-Yuan Dai Perrard; Xueying Peng; Joe L Raya; Alfredo A Hernandez; Collin G Johnson; William R Lagor; Henry J Pownall; Ron C Hoogeveen; Scott I Simon; Frank M Sacks; Christie M Ballantyne; Huaizhu Wu Journal: Arterioscler Thromb Vasc Biol Date: 2019-10-17 Impact factor: 8.311